Two cell lines that exemplify erythropoietin (EPO) receptor-positive tumors, human renal carcinoma cell lines RCC and the myelomonocytic leukemia cell line U937, were investigated for the apoptosis-modulatory potential of EPO. Cells cultured in the presence of EPO exhibited an elevated apoptotic response to cancer chemotherapeutic agents such as daunorubicin (Dauno) and vinblastine (VBL). Chemosensitization by EPO did not involve an increase in p53 activation, yet correlated with enhanced Bax/Bak-dependent mitochondrial membrane perturbation and caspase maturation. In vitro monotherapy with Dauno or VBL induced the degradation of IjBa, provoked the translocation of NF-jB p65/50 to the nucleus and stimulated the expression of an NF-jBactivatable reporter gene. All these signs of NF-jB activation were perturbed in the presence of EPO. Inhibition of JAK2, one of the receptor-proximal elements of EPO-mediated signal transduction, greatly diminished the EPO-mediated chemosensitization and NF-jB inhibition. EPO lost its death-facilitating effects in the presence of an NF-jB inhibitor, underscoring the cause-effect relationship between EPO-mediated chemosensitization and NF-jB inhibition. Altogether, these results suggest that, at least in a specific subset of tumors, EPO receptor agonists can prevent activation of the NF-jB pathway, thereby enhancing the propensity of EPO receptorpositive tumor cells to undergo apoptosis. Oncogene (2005) 24, 737-745.
Introduction
Antiapoptotic pathways constitute a major problem in anticancer chemotherapy. At a first level, apoptotic pathways are partially disabled in tumor cells, as a nearto-definitory hallmark of cancer (Hanahan and Weinberg, 2000; Debatin et al., 2002) . At a second level, after an initial success with a partial or near-to-complete therapeutic response to chemotherapy, chemoresistant tumors emerge and relapse. Chemoresistance may result from the Darwinian selection of resistant clones. Moreover, cytotoxic agents can elicit an active epigenetic response leading to the expression of antiapoptotic genes, for instance as a result of the activation of the transcription factors HSF-1 (Jolly et al., 1999) , HIF (Minet et al., 2000) or NF-kB (Wang et al., 1996; Gilmore, 1999; Smahi et al., 2002) .
The five members of the NF-kB family form dimmers, which, under nonstimulated conditions, are retained in the cytoplasm through interactions with inhibitory molecules of the IkB family. Following activation by a number of stimuli that include cytokines, various stress signals, bacterial and viral products, the IkB molecules get phosphorylated and degraded by the ubiquitinproteasome pathway Karin, 1999; Karin and Lin, 2002) . This liberates the NF-kB dimmers, which are free to translocate to the nucleus and activate their target genes. Although a great variety of stimuli activate NF-kB, apparently all the respective signaling pathways converge at the level of the IKK complex (composed of two catalytic subunits, IKKa and IKKb, and a regulatory subunit, NEMO/IKKg), which is responsible for the phosphorylation of the IkBs (Yamaoka et al., 1998; Karin, 1999) .
The main connection between NF-kB and cancer lies in the ability of this family of transcription factors to induce the expression of antiapoptotic genes such as BclxL (Baldwin, 1996) , IAP , A1 (Wang et al., 1999) , IEX-1L (Wu et al., 1998) and Gadd45b (De Smaele et al., 2001) . Apart from protecting tumor cells from apoptosis, NF-kB regulates genes that promote tumor growth and survival. For example, NF-kB induces the expression of cyclin D1 and c-Myc, thus stimulating cellular proliferation Kaltschmidt et al., 1999) . NF-kB also increases the expression of Cox2, another gene involved in tumor growth In addition, NF-kB controls the expression of genes involved in invasion of surrounding tissues by tumor cells and ultimately in metastasis, such as cellular adhesion molecules (ICAM1, VCAM1), matrix metalloproteinases (MMP9), chemokine receptors (CXCR4) and urokinase-type plasminogen activator (uPA). Finally, NF-kB also contributes to angiogenesis through induction of VEGF Smahi et al., 2002) .
Targeting the NF-kB signaling pathway may therefore not only diminish the resistance of tumor cells to killing by some apoptotic reagents, but more generally might improve the efficacy of cancer therapies. As a proof-of-principle of this notion, an inhibitor of the 26S proteasome, PS-341/Bortezomib (commercial name: Velcade, a dipeptidyl boronic acid derivative), can be used to inhibit the degradation of endogenous NF-kB inhibitors, thereby suppressing the NF-kB pathway. PS-341/Bortezomib is now FDA-approved for the treatment of multiple myeloma, and thus constitutes the first example of successful anticancer treatment targeting NF-kB (Kane et al., 2003; Richardson et al., 2003) . However, PS-341/Bortezomib is likely to have other effects not related to NF-kB Williams and McConkey, 2003) , and more-specific NFkB inhibitors are being developed.
Instead of directly intervening on the NF-kB pathway, it may be attempted to activate physiological signal transduction pathways that inactivate NF-kB or prevent its activation. Recently, it has been described that human growth hormone (GH) can sensitize U937 cells to TNF or daunorubicin (Dauno)-induced apoptosis by inhibiting the NF-kB pathway (Cherbonnier et al., 2002; Cherbonnier et al., 2003) . Since the receptors for GH and erythropoietin (EPO) share structural features (Bazan, 1990) and both similarly activate the JAK2/ STAT5 pathway (Parganas et al., 1998) , we wondered whether EPO might be used as an NF-kB-inhibitory, chemosensitizing agent. Here, we report that EPO indeed has such effects and demonstrate that it acts in a JAK2-dependent pathway to stabilize IkB, to prevent the nuclear NF-kB translocation and to prevent NF-kB transactivation. These results may have far-reaching clinical implications for the treatment of tumors that express EPO receptors.
Results and discussion

Chemosensitizing effect of EPO via mitochondriondependent apoptosis
Both human renal carcinoma cell line RCC and the human myeloid leukemia cell line U937 express significant amounts of EPO receptors on the plasma membrane, as determined by immunofluorescence and cytofluorometric analyses (Figure 1) . When testing the effect of recombinant EPO on the chemotherapy responses of these cells in vitro, we found that RCC underwent a higher degree of apoptosis with a combination of Dauno and EPO or vinblastine (VBL) plus EPO than with either of these agents alone. This chemosensitizing, proapoptotic effect of EPO was detectable both at the level of the frequency of cells losing the mitochondrial transmembrane potential (DCm, detectable with 3,3 0 dihexyloxacarbocyanine iodide (DiOC 6 (3))) and at the level of cells undergoing secondary necrosis (which incorporate the dye DAPI) (Figure 2a ). Similar effects were found when RCC were stably transfected with EPO, a manipulation that increased the propensity of RCC cells to undergo apoptosis in response to Dauno and VBL, as compared to vector-only transfected controls (Neo) (Figure 2b ). Moreover, U937 cells exhibited a more pronounced DCm dissipation and loss of viability (here quantified with propidium iodide (PI)) with EPO plus Dauno as compared to Dauno-only treated cells (Figure 2c ). This chemosensitizing effect of EPO can be attributed to bona fide apoptosis because the pan-caspase inhibitor Boc-D.fmk (BOAsp-fluoromethylketone) largely inhibited the EPO-enhanced DCm dissipation and cell death (Figure 2d ). Similar results were obtained when another caspase inhibitor, Z-VAD.fmk, was used (not shown). Of note, there was no evidence that EPO would exacerbate the activating phosphorylation of p53 on Ser 15 and 46, as detectable in RCC cells (Figure 3 ), or that EPO would enhance the activation of p53-inducible reporter genes (not shown). Accordingly, EPO had a chemosensitizing effect in p53-negative U937 cells, which provides a formal proof that cell death-enhancing effect is p53-independent. However, EPO did enhance the Dauno-driven activation of Bax or Bak, both in RCC cells (Figure 4a ) and in U937 cells (Figure 4b ), as determined by antibodies recognizing the exposed Ntermini of 'activated' Bax and Bak (Griffiths et al., 1999; Nechushtan et al., 1999) . Altogether these data suggest ) were stained with a specific anti-human EPO receptor mAb (anti-rhEPO) or with a mouse isotypic control, followed by cytofluorometric analysis. The U937 cells were also stained with anti-rhEPO after a 30 min incubation with recombinant EPO (5 IU, blue line, which inhibits anti-rhEPO binding), compared to the staining with the second Ab alone (purple line) an enhanced triggering of mitochondrial apoptosis in the context of EPO-mediated chemosensitization.
EPO-mediated chemosensitization through JAK2 activation
When EPO is added to U937 cells, it causes an increase in the abundance of a phosphotyrosilated protein of B130 kDa, which is the same molecular weight as that of JAK2, in accord with the fact that EPO activates the JAK2/STAT5 pathway (Oda et al., 1998) . Immunoprecipitation of JAK2, followed by blotting with an antiphosphotyrosine antibody indeed confirmed that this protein is JAK2. Addition of the AG490, a chemical inhibitor of JAK2 (Meydan et al., 1996) , reduced the (auto)phosphorylation of this protein (Figure 5a ). Importantly, the JAK2 inhibitor AG490 also reversed the chemosensitizing effect of EPO. The gain of apoptosis induction conferred by EPO was totally annihilated by AG490 (Figure 5b ,d) as well as by JAK2-specific siRNA (Figure 5c ), as could be determined using several different read-outs for the determination of apoptosis, namely DiOC 6 (3)-detectable DCm loss, PI-detectable plasma membrane permeabilization (Figure 5b ), accumulation of the proteolytically activated, mature caspase-3 17 kDa subunit or cleavage of the nuclear caspase substrate PARP (Figure 5d ). In conclusion, it seems that EPO sensitizes to apoptosis via JAK2 activation.
EPO curtails chemotherapy-induced NF-kB activation by JAK2-dependent stabilization of IkB
Treatment of U937 or RCC cells with Dauno or VBL stimulates the activation of NF-kB target genes as indicated by the selective activation of a luciferase reporter gene construct placed under the control of NFkB (Figure 6a,b) . This NF-kB-activating effect was blunted by EPO, suggesting that EPO may interfere with the chemotherapy-elicited cytoprotective NF-kB pathway. Accordingly, we found that transient transfection with the IkB super-repressor (IKSR, a non-phosphorylable S32A S36A mutant of IkB) (Kaltschmidt et al., 1999) sensitized the cells to VBL or Dauno-induced apoptosis, exactly as EPO did. Importantly, IKSR transfection actually eliminated the chemosensitizing effect of EPO, a finding that strongly suggests that modulation of the NF-kB pathway accounts for the action of EPO (Figure 6c ). What are then the mechanisms of EPO-mediated NF-kB inhibition? VBL enhances NF-kB binding to nuclear DNA in an EPO-inhibitable fashion, as determined by electrophoretic mobility shift assays (EMSAs) (Figure 7a ). Accordingly, treatment with VBL (not shown) or Dauno induced the translocation of NF-kB from the cytoplasm to the nucleus. EPO, however, favored the cytoplasmic retention of NF-kB, unless AG490 was used to block EPO-induced JAK2 activation (Figure 7b ). Correlating with these findings, we found that in all models of chemotherapy evaluated in this study (U937 or RCC treated with VBL or Dauno), IkB was degraded, within several hours (Figure 7c ). EPO treatment led to the stabilization of IkB (Figure 7c ), and this EPO effect was suppressed by JAK2 inhibition with AG490 ( Figure 7d ). In synthesis, these data indicate that EPO can stabilize IkB in a JAK2-dependent fashion.
Concluding remarks
A number of cancer cell types can express EPO receptors. This applies to a series of solid tumors (e.g. renal cancer and breast cancer) (Westenfelder and Baranowski, 2000; Acs et al., 2001) 
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Co. GAPDH Figure 3 Effect of EPO on drug-induced p53 phosphorylation. RCC were exposed Dauno (5 mM) or to VBL (2 mM) for 24 h, and cell extracts were subjected to immunoblotting with Abs specific to phosphorylated form of Ser 15 (p53S15P) or Ser 46 (p53S46P) of the p53 protein Fine et al., 2004) . Here, we show that two very different tumor cells that express EPO receptors (Figure 1 ) exhibit an identical behavior as far at the effect of EPO on chemotherapy-induced apoptosis is concerned. EPO sensitizes both RCC and U937 cells to Dauno or VBL, thus facilitating their apoptosis induction, as detectable by measuring DCm loss (Figure 2 ), Bax/Bak activation (Figure 4 ), caspase activation ( Figure 5 ) and loss of the plasma membrane integrity (Figure 2 ). These effects do not involve an increase in p53 activation (Figure 3) , and rather can be attributed to an inhibition of the NF-kB pathway. Dauno or VBL, given as a monotherapy, activates the degradation of IkB ( Figure  7c,d ) and stimulates the translocation of NF-kB to the nucleus (Figure 7b ), leading to the binding of NF-kB to suitable promoter elements (Figure 7a ) and the expression of NF-kB target genes ( Figure 6 ). However, in the presence of EPO, none of these signs of NF-kB activation occur (Figures 6 and 7) . Inhibition of JAK2, one of the receptor-proximal elements of EPO- Figure 5 JAK2 is required for EPO-mediated chemosensitization. (a) JAK2 phosphoylation induced by EPO. U937 cell were exposed to EPO (5 IU/ml, 10 min), after preincubation (1 h) with or without tyrphostin AG490 (50 mM). Immunoblots of total extracts were analysed for the presence of proteins staining with an anti-phosphotyrosine antibody (upper panel) or with an anti-JAK2 antibody (middle panel). Alternatively, the lysates were immunoprecipitated with anti JAK2-labeled agarose-protein A beads and analysed with an anti-phosphotyrosine Ab (lower panel). (b) The Jak2 inhibitor AG490 abolishes EPO-mediated chemosensitization. U937 cells were preincubated (1 h) with or without AG490 (50 mM) prior to stimulation with Dauno (0.25 mM), with or without EPO (10 IU/ml) for 24 h. The percentage of cells incorporating low levels of DiOC 6 (3) (left panel) or high levels of PI (right panel) were determined by cytofluorometry (X þ s.d. of triplicates). (c) Abolition of EPO-mediated chemosensitization by JAK2-speficic siRNA. RCC cells were treated with a JAK2-specific or control siRNA and 48 h later, the cells were exposed to VBL (200 nM), Dauno (5 mM), with or without EPO (10 IU/ml) for 24 h, followed by DiOC 6 (3) staining and FACS analysis to determine specific apoptosis, after subtraction of control values. (d) Extracts from U937 cells treated with the indicated dose of Dauno (24 h) before lysis. Caspase-3 activation was determined using an antiserum recognizing both the pro-caspase-3 (B33 kDa) and its large subunits. Moreover, the cleavage of PARP to a 85-kDa fragment was determined mediated signal transduction (Oda et al., 1998) completely abolishes EPO-mediated chemosensitization ( Figure 5 ) and NF-kB inhibition ( Figure 7) . As a further proof of the cause-effect relationship between EPO-mediated chemosensitization and NF-kB inhibition, EPO lost its proapoptotic effects in the presence of an NF-kB inhibitor (Figure 6c) .
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The data reported in this paper suggest that EPO treatment may have positive effects when combined with chemotherapeutic regimes. At present, EPO is frequently and successfully used to palliate chemotherapy-induced anemia, improving quality of life of the patients (Littlewood and Mandelli, 2002; Schwartzberg et al., 2003; Adams et al., 2004) . EPO is also frequently considered a cytoprotective agent with a broad spectrum of action, in particular in the nervous system (Ghezzi and , although these effects are probably not mediated by the EPO receptor (Leist et al., 2004) . In breast cancer, phase III trials on the use of EPO had to be interrupted because EPO enhanced tumor progression and cancer-related death in a small yet substantial fraction of patients, perhaps dues to its angiogenic properties (Leyland-Jones, 2003; Yasuda et al., 2003) . However, such adverse effects have not been reported for other cancers (Littlewood and Mandelli, 2002; Schwartzberg et al., 2003; Adams et al., 2004; Mittelman et al., 2004) . As a result, it may be worthwhile to investigate in preclinical models whether the synchronized treatment with EPO and chemotherapeutic agents (instead of the application of EPO after the cytotoxic agent) may have beneficial effects on EPO receptorpositive cancers. Irrespective of these considerations, our data illustrate the feasibility to exploit physiological signal transduction pathways elicited by natural hormones to manipulate the NF-kB pathway for chemosensitization.
Materials and methods
Cell and culture conditions
Human myeloid leukemia U937 cells were cultured in RPMI 1640 (Bio-Whittaker) supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 IU/ml penicillin and 100 g/ml streptomycin. Human renal carcinoma cell lines (RCC, kindly obtained from E Angevin, IGR, France, were maintained in culture as described (Durrbach et al., 1999) . The presence of EPO receptors was determined by cytofluorometry using a specific mouse antihuman EPO receptor mAb IgG2b (R&D Systems) or a control isotypic IgG2b mAb (Caltag Laboratories), both revealed with an FITC-labeled goat anti-mouse IgG2b (Jackson Immuno Research Laboratories). RCC cells were transfected with the human EPO gene subcloned into a pCEP4 vector as described . Transfected cells were selected upon selection in G418-enriched medium (0.5 mg/ml, Life Technology, Paisley, Scotland) and EPO secretion and the supernatant was confirmed by ELISA (R&D Systems). (Zamzami et al., 1995b; , followed by a 15 min staining with either 5 mg/ml PI (Sigma, St-Louis, MO, USA) or with 5 mg/ml 4 0 ,6-diamidino-2-phenylindole diaminidophenylindol, dihydrochloride (DAPI, Molecular Probes) (Zamzami et al., 1995a) . In some experiments, cells were preincubated 1 h with 50 mM tyrphostin AG490 (Calbiochem, CA, USA). To determine the apoptotic exposure of the N-termini of Bax or Bax, cells were permeabilized with digitonin (Perfettini et al., 2004) , and stained with antibodies specific for activated Bak (Ab-1, Oncogene) or Bax (mAb 6A7, Pharmingen), revealed with FITC-labeled goat anti-mouse antibodies (Pharmingen).
Measurement of apoptosis-associated parameters
Transfection and RNA interference
Renal carcinoma cells were transiently transfected with jetPEIt-FluoF, as recommended by the manufacturer (Qbiogene) and cultured for 24 h prior to 12 h stimulation with 0.5 mM Dauno or with 0.005 mM VBL, in the presence or not of EPO. Apoptosis was assessed after 15 min at 371C with 150 nM tetramethylrhodamine methyl ester TMRME staining, followed by DAPI staining . RNA interference of JAK2 expression was obtained using a JAK-2-specific small interfering RNA (siRNA) (sense strain: 5 0 GAA GAG CAC CUA AGA GAC UdTdT-3 0 ) or, as a control, a firefly luciferase-specific siRNA 
Immunoblots and immunoprecipitation
To measure, caspase activation, lysates from 10 6 cells exposed for 24 h to Dauno or vinblastin, were separated on a SDSpolyacrylamide gel and electroblotted onto PVDF membranes. A polyclonal rabbit antibody was used to detect the 32-kDa pro-caspase-3 and the subunits of active caspase-3 (Pharmingen, San Diego, CA, USA). Cleavage of PARP was determined using the mouse C2-10 mAb (purchased from G Poirier, Montreal University, Canada). Blots were stained with either anti-rabbit peroxidase-labeled or anti-mouse peroxidase-labeled second Ab (Amersham, Amersham, UK) and were revealed by chemiluminescence using a CDD camera (Fuji). For measurement of p53 phosphorylation, cellular extracts (50 mg per lane) were subjected to immunoblots using antibodies specific for phosphorylated form of Ser 15 (p53S15P) and 46 (p53S46P) (Cell Signalling Technology) or glyceraldhyde-3-phosphate dehydrogenase (GAPDH, Chemicon) as a loading control. JAK-2 phosphorylation was assessed by immunoprecipitation. Briefly, U937 cell lysates were immunoprecipitated with anti JAK2-labeled agaroseprotein A beads (Upstate Biotechnology, NY, USA). Eluted fractions were blotted onto PVDF membranes and hybridized with anti-phosphotyrosine antibodies (Upstate Biotechnology) and revealed with peroxidase-labeled goat anti-mouse Abs (Amersham). Alternatively, whole-cell lysates were analysed by immunoblotting using rabbit antisera specific for IkBa (SantaCruz Biotechnology) or actin (Sigma).
Luciferase reporter assays
To assess the transactivation potential of NF-kB, we used a Luciferase-reporter plasmid containing three tandem repeats of NF-kB consensus sequence upstream of a conalbumin minimal promoter driving the luciferase gene and a corresponding control vector (as previously described in (Besancon et al., 1998) . In total, 10 7 U937 cells were transiently transfected by electroporation (0.24 kV, 960 mFd) using a BioRad apparatus and cultured for 12 h prior to a 2 h stimulation with 1 or 5 mM Dauno with or without EPO. RCC were transiently transfected with Effecten R , as recommended by the manufacturer (Quiagen) and cultured for 24 h prior to a 5 h stimulation with 5 mM VBL with or without EPO. Cells extracts were prepared with 50 ml lysis buffer (Promega, Charbonnie`res, France) and 10 ml of supernatant were mixed with 50 ml of luciferase assay reagent (Promega) and analysed on a Microplate Luminometer. Results were expressed as arbitrary units.
EMSAs NF-kB measurement by EMSAs was performed as reported (Cherbonnier et al., 2003) . Renal carcinoma cell lines were cultured for 2 h in the absence or in the presence of 2 mM of VBL alone or in addition to various doses of EPO. Nuclear extracts were prepared in lysis buffer (20 mM HEPES (pH 7.9), 350 mM NaCl, 1 mM EGTA, 1 mM dithiothreitol, and complete protease inhibitors from Roche). Extracts were then mixed with binding buffer (25 mM Tris HCl pH 8, 50 mM KCl, 6.25 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM dithiothreitol, 10% glycerol) and poly[dI-dC] 1 mg/ml) and g-32 P-labeled NF-kB probe by T4 polynucleotide kinase and incubated for 30 min at room temperature. Specificity was assessed by incubating nuclear extracts obtained from VBL-stimulated cells with nonradiolabeled NF-kB probe (5 0 -ACAAGGGACTTT CCGCTGGGGACTTTCCAG-3 0 ) or mutated NF-kB oligonucleotide probe (5 0 -ACAACTCACTTTCCGCTGCTCAC TTTCCAG-3 0 ).
Immunofluorescence 10 5 U937 were cytospun and fixed in 3% paraformaldehyde for 30 min at 41C. Cells were then permeabilized with Triton X-100 for 5 min at room temperature, washed in PBS and stained with anti-p65 rabbit polyclonal Abs (Santa Cruz Biotechnology), revealed with a fluorescein-labeled goat anti-rabbit polyclonal Abs. Cells were examined with an epifluorescent microscope (Leica, Germany).
Abbreviations anti-rhEPO, anti-human EPO receptor antibody; Dcm, mitochondrial transmembrane potential; DAPI, 4 0 , 6-diaminidino-2-phenylindole; Dauno, daunorubicin; DiOC 6 (3), 3, 3 0 dihexyloxacarbocyanine iodide; EPO, erythropoietin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP, mitochondrial membrane permeabilization; p53S15P, p53 with phosphorylated serine 15; p53S46P, p53 with phosphorylated serine 46; PI, propidium iodide; VBL, vinblastine; Boc-D.fmk, BOAsp-fluoromethylketone.
